STATISTICAL ANALYSIS PLAN

NCT Number:	NCT03724916
Study Title:	A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
Study Number:	TAK-079-2001

SAP Amendment and Date:

Version 2.0 : 19 November 2021



STATISTICAL ANALYSIS PLAN Study Number: TAK-079-2001 Study Title: A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus Phase: 1b Version: Finc¹ .ed by: sed on: Protocol Version: Amendment 01: Market 01: Protocol Date: 19 February 2019: Market 01: Protocol Date: 19 February 2019: Market 01: Protocol Date: 19 February 2019: Protocol Pr

Prepared by:

Based on:

Property of Ta

Page 2 of 21 19-NOV-2021

REVISION HISTORY

v el sion	Approval Date	r rimary Rationale for Revision
Original version	21-DEC-2020	Not applicable
2.0	19-NOV-2021	To make SAP consistent with Amendment 01 of the protocol and to clarify statistical analysis methods, as outlined in Section 9.4
athortakeda	Fornoncomme	Primary Rationale for Revision Not applicable To make SAP consistent with Amendment 01 of the protocol and to clarify statistical analysis methods, as outlined in Section 94.

TABLE OF CONTENTS	-
1.0 OBJECTIVES, ENDPOINTS AND ESTIMANDS	7.50
1.1 Objectives	
1.1.1 Primary Objective	<u>S.7</u>
1.1.2 Secondary Objective(s)	7
1.1.3 Exploratory Objective(s)	
1.2 Endpoints	7
1.2 Endpoints 1.2.1 Primary Endpoint(s) 1.2.2 Secondary Endpoint(s)	7
1.2.2 Secondary Endpoint(s)	7
1.2.3 Exploratory Endpoint(s)	7
2.0 STUDY DESIGN	8
3.0 STATISTICAL HYPOTHESES AND DECISION RULES	9
3.1 Statistical Hypotheses	9
3.2 Multiplicity Adjustment	9
4.0 SAMPLE-SIZE DETERMINATION	9
5.0 ANALYSIS SETS	10
 3.1 Statistical Hypotheses	10
5.2 PK Analysis Set	10

Page 3 of 21 19-NOV-2021

1.1 Ob1	ectives
5	Primary Objective
	Secondary Objective(s)
	Exploratory Objective(s)
1.2 End	lpoints

TAK-079-2001

Statistical Analysis Plan Final v2.0

3.2 N	Vultiplicity Adjustment	9
4.0 SAM	Multiplicity Adjustment	9
5.0 ANA	ALYSIS SETS	10
5.1 S	Safety Analysis Set	10
5.2 P	PK Analysis Set PD Analysis Set mmunogenicity Analysis Set	10
5.3 P	PD Analysis Set	10
5.4 II	mmunogenicity Analysis Set	10
6.0 STA	TISTICAL ANALYSIS	10
6.1 0	General Considerations	10
6.1.1		
6.2 D	Disposition of Subjects	11
6.3 E	Demographic and Other Baseline Characteristics	11
6.3.1	Demographics	11
	20 ⁰⁰ Medical History	
6.4 OP	Prior and Concomitant Medications	12
65 E	Efficacy Analysis	
6.5.1	Primary Endpoints Analysis	12
6.5.2	5 1 5	
Q ⁽⁰⁾ 6.5.3	1 5 1 5	
6.6 S	Safety Analysis	
6.6.1	Adverse Events	14
6.6.2	2 Clinical Laboratory Evaluations	15

TAK-079-2001 Statistical Analy	vsis Plan <i>Final v2.0</i>	Page 4 of 2 19-NOV-202
6.6.3	Vital Signs	1
6.6.4	12-Lead ECGs	1
6.6.5	Extent of Exposure and Compliance	1
6.7 Ph	armacokinetic, Pharmacodynamic,	Analyses
6.7.1	Pharmacokinetic Analysis	
6.7.2	Pharmacodynamic Analysis	1
6.8 Im	munogenicity Analysis	1
6.9 Int	erim Analyses	1
7.0 REFE	RENCES	
8.0 CHAN	GES TO PROTOCOL PLANNED ANALYSES.	1
9.0 APPE	NDIX	1
9.1 Ch	anges From the Previous Version of the SAP	
9.2 Ar	alysis Software	2
9.3 Ph	armacodynamic Parameters	
	sis Plan Final v2.0 Vital Signs 12-Lead ECGs Extent of Exposure and Compliance 12-Lead ECGs Extent of Exposure and Compliance 12-Lead ECGs armacokinetic, Pharmacodynamic, Pharmacokinetic Analysis Pharmacodynamic Analysis Pharmacodynamic Analysis erim Analyses Analysis RENCES GES TO PROTOCOL PLANNED ANALYSES NDIX anges From the Previous Version of the SAP alysis Software Div armacodynamic Parameters Div Andread Analysis Analysis Software Div Analysis Software Div Analysis Parameters Div Analysis Andread Div Analysis Parameters Div Analysis Div Analysis Div Analysis Div Analysis Div Analysis Div Analysis Div	
	ame	
	c ^{ot}	
	offic	
	at the	
	5°.	
X	-	
×		
*10.		
Ś		

Page 5 of 21 19-NOV-2021

ABBREVIATIONS

Abbreviation	Term
ADA	Term antidrug antibody(ies) adverse event area under the concentration-time curve confidence interval maximum observed concentration
AE	adverse event
AUC	area under the concentration-time curve
CI	confidence interval
	maximum observed concentration Common Terminology Criteria for Adverse Events trough concentration percent coefficient of variation electrocardiogram
Cmax	maximum observed concentration
CTCAE	Common Terminology Criteria for Adverse Events
Ctrough	trough concentration
%CV	percent coefficient of variation
ECG	electrocardiogram
eCRF	electronic case report form (refers to any media used to collect study data [ie, paper or electronic])
ICF	informed consent form
Ig	Immunoglobulin
IgA	Immunoglobulin A
IgG	immunoglobulin G
IgM	imnunoglobulin M
MedDRA	Medical Dictionary for Regulatory Activities
NK	natural killer
NK PB PD	plasmablast
PD	pharmacodynamic(s)
PK	pharmacokinetic(s)
PD PK PT PTE QTc	preferred term
PTE	pretreatment event
QTc	corrected QT interval
SAE	serious adverse event
SAP	statistical analysis plan
SC	subcutaneous
SD	standard deviation

TAK-079-2001 Statistical Analysis Plan *Final v2.0*

Page 6 of 21 19-NOV-2021

Abbreviation	Term
SLE	systemic lupus erythematosus
SOC	system organ class
SOE	schedule of events
TEAE	treatment-emergent adverse event
	i Cal
WHO	World Health Organization
of Takeda. For	systemic lupus erythematosus system organ class schedule of events treatment-emergent adverse event World Health Organization World Health Organization Montoonneerical use on Mandaublectual the anti-catheouse on Mandaublectual the an

1.0 **OBJECTIVES, ENDPOINTS AND ESTIMANDS**

remary Objective The primary objective of this study is to evaluate the safety and tolerability of TAK-079 in The comparison with matching placebo, administered once every 3 weeks over a 12-week date for the period in patients with active systemic lupus erythematosus (ST EVERT)

1.1.2 Secondary Objective(s)

The secondary objective of the study is to assess the PK, PD, and immunogenicity of TAK-079 administration over a 12-week dosing period.

1.1.3 **Exploratory Objective(s)**

1.2 Endpoints

1.2.1 **Primary Endpoint(s)**

15° on Wal The primary endpoints of this study will evaluate the safety and tolerability of TAK-079 to include the incidence, type, and grade of adverse events (AEs), as well as the percentage of patients with ≥ 1 AE leading to study treatment discontinuation.

1.2.2 Secondary Endpoint(s)

The secondary endpoints will include:

- 1. Pharmacokinetic evaluations of TAK-079.
- 2. Pharmacodynamics evaluations of TAK-079.
- 3. Immunogenicity assessments of TAK-079.

1.2.3 Exploratory Endpoint(s)



2.0 STUDY DESIGN


ns of USE This phase 1b double-blind, placebo-controlled, multicenter study will evaluate the safety PK, and PD of TAK-079 in a study population receiving standard principal investigator-directed background therapy for moderate to severe SLE.

The study will compare active TAK-079 with matching placebo in combination with a background SLE standard treatment, across 3 sequentially enrolling cohorts in a double-blinded study design. A 3:1 randomization, within each cohort, will assign each patient to: (1) TAK-079 administered as a single SC injection every 3 weeks for 12 weeks (total of 4 doses); or, (2) matching placebo given in same route and schedule (see Protocol Figure 2.a). Each cohort will enroll 8 patients; 6 patients will be randomized to TAK-079 dosing and 2 patients to TAK-079 matching placebo. After each dosing day, patients will return for postdose assessments as outlined in Protocol Table 3.a and Protocol Table 3.b.

Following completion of the 12-week dosing period, patients will return for an additional 12 week safety follow-up period, completing safety visits every 4 weeks and ending this postdosing study period with a safety visit on Week 24. Based on clinical assessments at this visit, patients may complete the study or may advance to the long-term safety follow-up period, for an additional on-study 12-week safety monitoring period (based on end-of-study criteria outlined in relate Property of Takeda. For non-comme Protocol Table 9.c), during which time the end of study parameters not met and deemed by the principal investigator as study related, will continue to be assessed and followed as outlined in

Page 9 of 21 19-NOV-2021

Protocol Figure 2.a TAK-079-2001 Study Cohort Reviews



3.0 STATISTICAL HYPOTHESES AND DECISION RULES

3.1 **Statistical Hypotheses**

No formal tests of statistical hypotheses are planned.

Multiplicity Adjustment 3.2

No multiplicity adjustments are planned.

SAMPLE-SIZE DETERMINATION 4.0

This study is not statistically powered for any hypothesis testing. The sample size of 6 active and 2 placebo patients for each of the 45 mg, 90 mg, and 135 mg dose groups (Cohorts A, B, and C, respectively) are considered to be sufficient to fulfill the study objectives of the evaluation of safety, tolerability, and PK of each cohort.

5.0 ANALYSIS SETS

5.1 Safety Analysis Set

The safety analysis set will consist of all patients who are enrolled and received at least 1 dose of study drug. Patients in this analysis set will be used for the study drug. Patients in this analysis set will be used for demographic, baseline characteristics and safety summaries.

5.2 **PK Analysis Set**

The PK analysis set will consist of all patients who receive study drug and have at least 1 the 30 measurable serum concentration.

5.3 **PD** Analysis Set

The PD analysis set will consist of all patients who receive study drug and have at least 1 postdose PD measurement.

5.4 **Immunogenicity Analysis Set**

The immunogenicity analysis set will consist of all subjects from the safety population who have the baseline immunogenicity sample and at least 1 postdose immunogenicity sample assessment. seon

STATISTICAL ANALYSIS 6.0

6.1 **General Considerations**

Continuous data will be summarized using the following descriptive statistics: number of subjects (N), mean, standard deviation (SD), median, minimum, and maximum, where appropriate. Where indicated, the coefficient of variation (%CV) and geometric mean may also be included in the summary of continuous data. Arithmetic means, geometric means, and medians will be presented to 1 more decimal place than the recorded data, and SDs will be presented to 2 more decimal places than the recorded data, where appropriate.

For PK related tables, mean, SD, median, minimum, and maximum will be rounded to 3 significant digits and CV% will presented to 1 decimal place.

Categorical data will be summarized using the number and percent of subjects for each category, where appropriate. Percentages will be reported to 1 decimal place.

Unless otherwise stated, baseline value is defined as the last observed value before the first dose of study medication.

There will be no visit windows.

For values with several non-missing measurements, for example triplicate ECGs, the average of triplicate assessments will be used.

TAK-079-2001	Page 11 of 21
Statistical Analysis Plan <i>Final v2.0</i>	19-NOV-2021

Subjects who receive placebo in each cohort will be pooled across the cohorts. All summaries

randling of Treatment MisallocationsFor analyses based on the safety, PK, PD, or immunogenicity analysis sets, subjects will be analyzed as treated, i.e., actual treatment. For analyses based on all randomized subjects will be analyzed as randomized, i.e., planned treatment.
6.2 Disposition 100

Disposition of Subjects

The summary and listing of disposition of subjects will be based on all randomized subjects. The number of subjects in the safety set will be presented. Disposition will be tabulated in terms of subjects who prematurely discontinued from study treatment, subjects who completed study treatment, subjects who prematurely discontinued from the study, and subjects who completed the study. Primary reasons for premature discontinuation from study or study treatment, as entered on the electronic case report form (eCRF), will also be tabulated. Percentages will be based on the number of subjects in the safety set.

In addition, the number of subjects randomized will be summarized for each country and site.

Major protocol deviations will be summarized and listed based on all randomized subjects. Protocol deviations related to COVID-19 will be summarized and listed.

The date of first dose, date of last dose, duration of treatment and the reason for premature discontinuation of study drug/study visit will be presented for each subject in listings.

Demographic and Other Baseline Characteristics 6.3

Demographics 6.3.1

Summary statistics will be presented for continuous variables (for example, age and weight). The number and percentage subjects within each category will be presented for categorical variables (for example, race and sex). Individual subject demographic and baseline characteristic data will be listed. Placebo data will be pooled across the cohorts.

Demographic variables of screen failure subjects and reasons for screen failures will be summarized for subjects who are screened, but not enrolled in the study.

Individual demographic characteristics, date of informed consent form (ICF), and reason for screen failure will be listed.

The analysis and listing of demographics and baseline characteristics will be based on the safety analysis set.

6.3.2 Medical History

Medical history refers to any significant conditions or diseases that stopped at or prior to informed consent or are ongoing at informed consent.

Medical history will be coded using the Medical Dictionary for Regulatory Activities (MedDRA, version 21.1 or higher) and will be summarized by treatment using System Organ Class (SOC) and MedDRA preferred term (PT). The table will include number and percentages of subjects, and will be sorted in alphabetical order by SOC. Within an SOC, PTs are sorted in decreasing frequency based on the total number of subjects. A subject will only be counted once within a particular class even if he/she has multiple conditions/symptoms. Summaries will be based on safety analysis set.

All medical history data will be presented in listings based on the safety analysis set.

6.4 Prior and Concomitant Medications

Concomitant medications, blood products, and procedures will be recorded from the first dose of TAK-079 or matching placebo, through the end of the safety follow-up period (i.e., end of safety follow-up visit in Week 24 or, when applicable, end of long-term safety follow-up visit in Week 36). Trade name and international nonproprietary name (if available), indication, and start and end dates of the administered medication are to be recorded. Medications will be coded using the World Health Organization Drug Dictionary (WHODD, B3 Global version SEP2018 or later). The number and percentage of patients taking prior medications and concomitant medications will be tabulated by WHO drug generic term based on safety analysis set.

All prior medications and concomitant medications data will be presented in listing. This listing will be based on safety analysis set. There will be no imputation for missing concomitant medication dates.

6.5 Efficacy Analysis

Efficacy endpoints will be summarized by descriptive statistics. Additionally, where applicable, analyses of treatment effects will be presented in terms of point estimates and 2-sided 95% confidence intervals (CIs). The safety analysis set will be used for all efficacy analyses.

6.5.1 Primary Endpoints Analysis

There are no primary efficacy endpoints for the study.

6,5,2 Secondary Endpoints Analysis

There are no secondary efficacy endpoints for the study.

6.5.3 Exploratory Endpoints Analysis

Page 13 of 21 19-NOV-2021

<i>Q⁴</i>				

Page 14 of 21 19-NOV-2021

, CO

6.6 Safety Analysis

Safety measures include AEs, clinical laboratory parameters, vital sign parameters, 12-lead ECG results, and other safety parameters. The safety analysis set will be used for all summaries of safety parameters.

For all safety summary tables stated under this section, the tables will be summarized by placebo, each TAK-079 dose level, and TAK-079 overall. Placebo data will be pooled across the dose levels.

6.6.1 Adverse Events

A Pre-Treatment Event (PTE) is defined as any untoward medical occurrence in a clinical investigation subject who has signed informed consent to participate in a study, but prior to administration of any study medication; it does not necessarily have to have a causal relationship with study participation.

An AE is defined as any untoward medical occurrence in a clinical investigation subject administered a drug; it does not necessarily have to have a causal relationship with this treatment. PTE and AE verbatim terms will be coded by SOC and PT using MedDRA (version 23.1 or higher).

Treatment-Emergent Adverse Events (TEAE)s will be defined as AEs that occur after the first dose of study drug received in the treatment period and until the end of safety follow up.

TEAEs will be presented by intensity. Serious TEAEs, TEAEs leading to study drug discontinuation, TEAEs leading to dose modification (e.g. described as dose delay, dose skipped) and TEAEs leading to death will also be summarized using SOC and PT.

When calculating the frequency and percentage of subjects who reported TEAEs, a subject will be counted only once for each SOC or PT when multiple TEAEs are coded to the same SOC or PT. For the intensity or relatedness summaries, if a patient reports multiple TEAEs coded to the same SOC or PT, the TEAE with maximum intensity or strongest relationship will be included in the summary.

AEs with missing intensity will be listed as such in the AE listings, but will be summarized as severe in summary tables. Similarly, if the relationship of an event is missing, the event will be considered as related but in listings it will be presented as missing.

TAK-079-2001	Page 15 of 21
Statistical Analysis Plan <i>Final v2.0</i>	19-NOV-2021

In general, AEs will be tabulated at the following levels: overall summary (subjects with at least 1 AE in any dose or treatment), the MedDRA SOC, and the MedDRA PT. The tables will include the number and percentage (N [%]) of subjects. The following summary tables will be IMSON generated for all cohorts:

- Overview of Treatment-Emergent Adverse Events.
- Treatment-Emergent Adverse Events by System Organ Class and Preferred Term. •
- Serious Treatment-Emergent Adverse Events by System Organ Class and Preferred • Term.
- Most Frequent (N>2) Non-Serious Adverse Events by Preferred Term. AE events of TAK-079 overall will be used to decide whether the event of $AE_{S} > 2$.
- Most Frequent (N>2) Non-Serious Adverse Events by System Organ Class and Preferred Term. AE events of TAK-079 overall will be used to decide whether the event of AEs >2.
- Drug-Related Treatment-Emergent Adverse Events by System Organ Class and Preferred • Term.
- Intensity of Treatment-Emergent Adverse Events by System Organ Class and Preferred Term.
- TEAE Overall, by Toxicity, Seriousness, Relatedness, and Discontinuation by SOC, HLT • and PT.

Data listings will be provided for PTEs, TEAEs, TEAEs leading to study drug discontinuation, TEAEs leading to dose modification of study drug with modification including dose delay and dose skipped, SAEs and AEs that resulted in death.

There will be no imputation for missing adverse events dates.

Clinical Laboratory Evaluations 6.6.2

Unless otherwise stated in the protocol, all laboratory samples are to be sent to the study central laboratory for analysis, under the conditions for handling and shipping as outlined in the study laboratory manual. If a patient has repeated laboratory values for a given time point, the value from the last evaluation will be used.

Clinical laboratory evaluations are obtained, handled, stored, and shipped to the designated central laboratory, in accordance to the laboratory manual. Clinical chemistry and hematologic assays are outlined Protocol Table 9.a and urinalysis assays are outlined in Protocol Table 9.b. Timings of these assessments should be in accordance to the study SOE (see Protocol Table 3.a and Protocol Table 3.b).

All laboratory test parameters will be displayed in individual subject data listings in both SI units and conventional (CV) units. For test results not in SI units, the conversion to SI units will be done using the known conversion factors. If necessary, SI units from the central laboratory may

TAK-079-2001	Page 16 of 21
Statistical Analysis Plan <i>Final v2.0</i>	19-NOV-2021

be converted to Takeda's preferred SI units. All summaries and analyses will be based on the values using these preferred SI units.

Study baseline will be used for change from baseline.

The actual values, change from baseline, and percent change from baseline in clinical laboratory parameters will be summarized. Figures of mean actual values and changes from baseline by visit will also be generated. Individual subject profiles over time for selected parameters may be plotted as needed.

CTCAE grading (version 4.03) for lab values are summarized by creating a shift table for the toxicity grades for baseline to worst toxicity grade post-baseline. All clinical laboratory data will be presented in both SI and conventional units in data listings.

6.6.3 Vital Signs

Individual results of vital signs that meet abnormal criteria and are clinically significant per the PI will be captured as an AE by the investigator.

A summary table of vital sign parameters by visit will be generated. All vital signs will be listed in a data listing.

6.6.4 **12-Lead ECGs**

A single 12-lead ECG is to be collected at the screening visit (for assessment of eligibility) and at the end of safety follow-up visit, and will be read locally.

Pre-dose triplicate 12-lead ECGs, obtained before each study dose, are to be collected just before PK sampling, during timeframes outlined in Protocol Table 3.a and Table 3.b.

Overall ECG interpretation category (normal, abnormal not clinically significant, abnormal clinically significant, not evaluable) is collected by eCRF at baseline and at each scheduled postbaseline visit. Shifts in ECG interpretation will be presented as cross-tabulations (baseline versus each post-baseline visit) of numbers of subjects with normal, abnormal not clinically significant, and abnormal clinically significant interpretations, not evaluable, with missing, if applicable, and total categories overall.

Rate-corrected QT interval (millisec) of electrocardiograph (QTc) will be calculated using Bazett's correction and Fridericia's correction, if necessary. The formulas are:

 $QTc (Bazett) = QT / (RR^{0.5})$

QTe (Fridericia) = $QT / (RR^{0.33})$

where RR = 60 / heart rate (bpm)

All ECG parameters will be listed in a data listing.

6.6.5 **Extent of Exposure and Compliance**

The total number of doses taken and the total amount of dose taken will be summarized descriptively in the pooled placebo group and TAK-079 arms.

Treatment compliance will be summarized in terms of the percent of scheduled doses received in the pooled placebo group and TAK-079 arms. The percent of scheduled doses received for each subject is defined as: [(Actual total number of doses taken) ÷ (Planed number of doses)]*100.

Analyses plicable The date and time of each dose for each subject will be reported in a data listing.

Pharmacokinetic, Pharmacodynamic, **6.7**

6.7.1 **Pharmacokinetic Analysis**

Due to sparse PK sampling, no noncompartmental analysis will be conducted. TAK-079 concentration-time profile will be summarized using descriptive statistics. Individual TAK-079 concentration-time data, individual Ctrough parameter (the last concentration reached before the next dose administration) and individual C_{max} parameter (the maximum observed concentration) will be presented in listings and tabulated using summary statistics by treatment group. Individual and mean concentration-time profiles will be plotted by treatment group. The PK analysis set will be used for summaries and analyses of PK parameters.

A population PK model may be developed. If developed, the population PK model may be reported separately. The analysis plan for the population PK analysis may be separately defined, and the results of these analyses may be reported separately.

6.7.2 Pharmacodynamic Analysis

Individual values, change from baseline, and mean change from baseline and/or percent change from baseline at different timepoints for placebo and each TAK-079 dose level will be calculated for the pharmacodynamic measures listed in Appendix 9.3 listed below.

- Serum immunoglobulin levels.
- Autoantibodies. Only subjects who are positive for a specific SLE antibody at baseline will be summarized for that autoantibody.

Descriptive summaries may include geometric mean and CV% where needed.

For PD parameters, figures of mean values and mean percent change from baseline will be generated. Mean percent change from baseline will not be plotted for measures related to receptor occupancy, instead mean change from baseline will be generated. Individual subject profiles over time for selected parameters may be plotted as needed.

The PD analysis set will be used for summaries, listings and analyses of PD parameters.

Page 18 of 21 19-NOV-2021

6.8 Immunogenicity Analysis

Immunogenicity analysis (ADA transient, persistent, negative, and titer) will be summarized using descriptive statistics as applicable. The immunogenicity analysis set will be used for all summaries of immunogenicity parameters.

(A) Transiently positive ADA response is defined as patients who have confirmed positive ADA status in 1 or 2 post baseline assessment(s).

(B) Persistently positive ADA response is defined as patients who have confirmed positive ADA status in more than 2 post baseline assessments.

A positive ADA assessment at each post baseline visit is defined as having either (1) a negative assessment at baseline and a positive assessment value, or (2) a positive value at baseline and the assessment value meets the criterion for treatment boosted ADA response (at least 4 times the baseline value.)

6.9 Interim Analyses

The Sponsor may perform unblinded reviews or analyses of data from one or more dose cohorts after all patients enrolled in those cohorts have completed the Safety Follow-up Period or prematurely discontinued from the study. The Sponsor would receive treatment assignments only for individual subjects within the pertinent cohorts while remaining blinded to treatment assignments of the other subjects. Details on the unblinding process and steps to minimize bias are described in the Data Access Management Plan.

7.0 REFERENCES

Not applicable.

8,0 CHANGES TO PROTOCOL PLANNED ANALYSES

Plans to potentially perform unblinded reviews of completed cohorts were not documented in the protocol but have been added to this analysis plan. The purpose of such analyses would be for internal planning by the Sponsor.

Due to sparse PK sampling, only a limited set of PK summaries will be provided. AUCs, and dose proportionality may not be evaluated.

9.0 APPENDIX

9.1 **Changes From the Previous Version of the SAP**

4 USE Changes made from the previous version of the SAP that have a material impact to the planned C statistical analysis methods are described below. In addition, there were textual changes purely to improve the flow, organization, and clarity. As these represent cosmetic changes with no impact to the planned statistical analyses, they are not included in the table below. 0

SAP Section	Change	Rationale for Change
6.1 General Considerations	Added clarification for presenting summaries of PK data.	To define the rule for presenting the summaries to be consistent with the data collected.
6.2 Disposition of Subjects	Updated analysis set for presenting disposition of subjects and the calculation of percentages.	For additional clarity of presenting the disposition.
6.2 Disposition of Subjects	Added statement for reporting protocol deviations related to COVID-19.	To add new summaries reporting COVID-19 related protocol deviations.
6.6.5 Extend of Exposure and Compliance	Updated the reporting of exposure and compliance to include the pooled placebo group. Added clarification on the calculation of compliance.	For comparison of the placebo group with the active groups.
6.7.2 Pharmacodynamic Analysis	Clarified the parameters to be reported for pharmacodynamics by updating the text and adding a table in the appendix.	For add clarification on the parameters to be reported.
6.8 Immunogenicity Analysis	Added definition of ADA transient and ADA persistent.	To add more concise definition.

Analysis Software 9.2

All data analyses and figures will be generated using SAS System® Version 9.4 or higher.

Pharmacodynamic Parameters 9.3

Table 1: Pharmacodynamic Parameters

	Parameter as Collected	Parameter Name to Present in TLFs
	B Cells % CLymphocytes Absolute Count Tube 2	B Cells/uL
	B cells %Lymphocytes Tube 2	B Cells %Lymphocytes
	CD27++HLADR++ PB %PB Tube 2	CD27++HLADR++ PB %PB
	CD27++HLADRdim/- PB %PB Tube 2	CD27++HLADRdim/- PB %PB
201	Granulocytes % of WBC Absolute Count Tube 2	Granulocytes/uL
\mathcal{Q}^{\prime}	Granulocytes % WBC singlets Tube 2	Granulocytes %WBC singlets
	Lymphocytes % of WBC Absolute Count Tube 2	Lymphocytes/uL
	Lymphocytes % WBC singlets Tube 2	Lymphocytes %WBC singlets
	Monocytes % of WBC Absolute Count Tube 2	Monocytes/uL



Parameter as Collected	Parameter Name to Present in TLFs
Monocytes % WBC singlets Tube 2	Monocytes %WBC singlets
NK Cells % of Lymphocytes Absolute Count Tube 2	NK Cells/uL
NK cells %Lymphocytes Tube 2	NK Cells %Lymphocytes
Plasma blasts %B cells Tube 2	Plasmablasts %B Cells
Plasma Cells % of B cells Absolute Count Tube 2	Plasma Cells/uL
Plasma cells %B cells Tube 2	Plasma Cells %B Cells
Plasmablasts % of B cells Absolute Count Tube 2	Plasmablasts/uL
Receptor Occupancy % Plasma cells	Receptor Occupancy %Calculation Plasma Cells (%)
Receptor Occupancy % Plasmablasts	Receptor Occupancy %Calculation Plasmablasts (%)
Receptor Occupancy % TAK/TSF+ B Cells	Receptor Occupancy %Calculation CD38+ B Cells (%)
Receptor Occupancy % TAK/TSF+ Granulocytes	Receptor Occupancy %Calculation CD38+ Granulocytes (%)
Receptor Occupancy % TAK/TSF+ Lymphocytes	Receptor Occupancy %Calculation CD38+ Lymphocytes (%)
Receptor Occupancy % TAK/TSF+ Monocytes	Receptor Occupancy %Calculation CD38+ Monocytes (%)
Receptor Occupancy % TAK/TSF+ NK Cells	Receptor Occupancy %Calculation CD38+ NK Cells
Receptor Occupancy % TAK/TSF+ T Cells	Receptor Occupancy %Calculation CD38+ T Cells (%)
T Cells % of Lymphocytes Absolute Count Tube 2	T Cells/uL
T cells %Lymphocytes Tube 2	T cells % Lymphocytes
TAK/TSF+ B Cells % Parent Absolute Count Tube 2	CD38+ B Cells/uL
TAK/TSF+ B cells % Tube 2	CD38+ B Cells %B Cells
TAK/TSF+ Granulocytes % Parent Absolute Count Tube 2	CD38+ Granulocytes/uL
TAK/TSF+ Granulocytes % Tube 2	CD38+ Granulocytes %Granulocytes
TAK/TSF+ Lymphocytes % Parent Absolute Count Tube 2	CD38+ Lymphocytes/uL
TAK/TSF+ Lymphocytes % Tube 2	CD38+ Lymphocytes %Lymphocytes
TAK/TSF+ Monocytes % Parent Absolute Count Tube 2	CD38+ Monocytes/uL
TAK/TSF+ Monocytes % Tube 2	CD38+ Monocytes %Monocytes
TAK/TSF+NK Cells % Parent Absolute Count Tube	CD38+ NK Cells/uL
TAK/TSF+ NK cells % Tube 2	CD38+ NK Cells %NK Cells
TAK/TSF+ T Cells % Parent Absolute Count Tube 2	CD38+ T Cells/uL
TAK/TSF+ T cells % Tube 2	CD38+ T Cells %T Cells
Lymphocytes AF647 Mean MFI Tube 2	Lymphocytes CD38 Mean MFI
Monocytes AF647 Mean MFI Tube 2	Monocytes CD38 Mean MFI
Granulocytes AF647 Mean MFI Tube 2	Granulocytes CD38 Mean MFI
T cells AF647 Mean MFI Tube 2	T Cells CD38 Mean MFI



Page 21 of 21 19-NOV-2021

Parameter as Collected	Parameter Name to Present in TLFs
NK cells AF647 Mean MFI Tube 2	NK Cells CD38 Mean MFI
B cells AF647 Mean MFI Tube 2	B Cells CD38 Mean MFI
Plasma blasts AF647 Mean MFI Tube 2	Plasmablasts CD38 Mean MFI
CD27++HLADR++ PB AF647 Mean MFI Tube 2	CD27++HLADR++ PB CD38 Mean MFI
CD27++HLADRdim/- PB AF647 Mean MFI Tube 2	CD27++HLADRdim/- PB CD38 Mean MFI
Plasma cells AF647 Mean MFI Tube 2	Plasma Cells CD38 Mean MFI
WBC count (x10 ⁶) (from Sysmex)	WBC count (x10 ⁶)
Plasma cells AF647 Mean MFI Tube 2 WBC count (x10^6) (from Sysmex)	onwand subject to the an

Drug: TAK-07	9 Protocol Number: TAK-079-2001
	A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and
Protocol Name:	Pharmacodynamics of TAK-079 in Combination With Standard Background
<u></u>	Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
	s Plan (SAP) Version Number: 2.0 Date: 19 NOV 2021
I coniirm	the final SAP for above noted study and approve the content for submission to the SAP approval team.
Biostatistics Au	thor Ph.D. Study Statistician
	Rare Disease TAU Statistics
	Print Name and Title
	■ ■
	Signer Name:
	Signing Reason: I am the author of this document
	Signing Time: 19-Nov-2021 23:06:48 JST 43EB1764F14349988EA20AB23CF25486
	Signature and Date (DD/MM/YYYY)
	Statistical Analysis Plan Approval by SAP Approval Team Members
i appro	ve the final SAP for the above study as it pertains to my area of expertise.
Note: An approve	
Note: An approve	
	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee.
	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee.
	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics
	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician
	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics
	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics
	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
SAP Signatory	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
SAP Signatory	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
SAP Signatory	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
SAP Signatory	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
SAP Signatory	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
SAP Signatory	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
SAP Signatory	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
SAP Signatory	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
SAP Signatory	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
SAP Signatory	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
SAP Signatory	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title
	r may delegate the review and approval of this document to an appropriately qualified and clearly identified (by name and title) designee. Ph.D. Statistician Statistics Rare Disease TAU Statistics Print Name and Title

